The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
SF3B1 mutations (SF3B1mut) in myelodysplastic syndromes (MDS) frequently involve codon K700E and have a favorable prognosis. The prognostic effect of non‐K700E SF3B1mut is uncertain.
Methods
The authors analyzed the clinicopathological features and outcomes of a single‐institution series of 94 treatment‐naive SF3B1mut MDS patients (18%) and 415 treatment‐naive SF3B1wt MDS patients and...
Background
Isocitrate dehydrogenase (IDH1 and IDH2) mutations commonly co‐occur with FMS‐like tyrosine kinase 3 (FLT3) mutations in patients with acute myeloid leukemia (AML).
Methods
The authors reviewed cases of patients with FLT3‐internal tandem duplication (FLT3‐ITD)–mutated AML with concurrent IDH mutations diagnosed between January 2011 and December 2018.
Results
A total of 91 patients...
Background
The impact of the allelic burden of ASXL1, DNMT3A, JAK2, TET2, and TP53 mutations on survival remains unclear in patients with newly diagnosed acute myeloid leukemia (AML).
Methods
The authors assessed bone marrow aspirates from 421 patients with newly diagnosed AML using next‐generation sequencing for ASXL1, DNMT3A, JAK2, TET2, and TP53 mutations, defined as the presence of mutations...
Background
The addition of midostaurin to induction chemotherapy improves survival in younger patients with newly diagnosed, FLT3–mutated acute myeloid leukemia (AML). Sorafenib is a potent multikinase inhibitor with efficacy when given as monotherapy. The authors investigated whether the addition of sorafenib to intensive induction chemotherapy improves outcomes in patients with FLT3‐internal tandem...
Background
The combination of all‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) has proven to be the most effective therapy for patients with acute promyelocytic leukemia (APL). The majority of the morbidity and mortality from APL therapy occur during the induction phase. The objective of the current study was to identify the risk factors associated with transfer to the intensive care unit...
Background
The outcome of older patients with newly diagnosed, Philadelphia chromosome (Ph)‐negative acute lymphoblastic leukemia (ALL) is poor. The combination of targeted therapy with low‐intensity chemotherapy is safe and effective. The objective of the current analysis was to compare the outcome of patients who received a combination of inotuzumab ozogamicin plus low‐intensity chemotherapy (mini–hyperfractionated...
Background
Clonal hematopoiesis of indeterminate potential (CHIP)‐associated mutations increase the risk of atherosclerotic heart disease. Comorbidities significantly impact the prognosis of patients with myelodysplastic syndromes (MDS). The objective of this study was to determine the association and impact of CHIP mutations with comorbidities in patients with MDS.
Methods
This retrospective analysis...
Background
The outcomes of patients with relapsed or refractory (R‐R) acute lymphoblastic leukemia (ALL) are poor. Inotuzumab ozogamicin and blinatumomab have single‐agent activity in R‐R ALL. Their addition to low‐intensity chemotherapy may further improve the outcomes of patients with ALL in their first relapse.
Methods
The chemotherapy was lower in intensity than conventional hyperfractionated...
BACKGROUND
The outcome of patients with higher‐risk myelodysplastic syndromes (MDS) after hypomethylating agent (HMA) failure is poor. This study evaluated the safety and activity of a combination of low‐dose clofarabine and cytarabine for these patients.
METHODS
Seventy patients with higher‐risk MDS who had no response, progressed, or relapsed after at least 4 cycles of HMA therapy were treated...
BACKGROUND
Predicting outcomes for patients with acute myeloid leukemia (AML) on the basis of pretreatment predictors has been the cornerstone of management. Posttreatment prognostic factors are increasingly being evaluated.
METHODS
Among 280 younger patients who were treated with intermediate‐dose cytarabine (total ≥ 5 g/m2) and idarubicin‐based induction chemotherapy and achieved remission, 186...
BACKGROUND
Both dasatinib and nilotinib are approved frontline therapy for chronic myeloid leukemia in chronic phase (CML‐CP) based on randomized trials compared with imatinib. However, no head‐to‐head comparison of dasatinib and nilotinib has been conducted in patients with newly diagnosed CML‐CP.
METHODS
The authors conducted a propensity score (PS) matched comparison of patients with CML‐CP...
BACKGROUNDRAS/RAF/mitogen‐activated protein kinase activation is common in myeloid malignancies. Trametinib, a mitogen‐activated protein kinase kinase 1 (MEK1)/MEK2 inhibitor with activity against multiple myeloid cell lines at low nanomolar concentrations, was evaluated for safety and clinical activity in patients with relapsed/refractory leukemias.
METHODSThis phase 1/2 study accrued patients with...
BACKGROUNDThe hypomethylating agents (HMAs) azacitidine and decitabine are most commonly used to treat patients with higher‐risk myelodysplastic syndromes (MDS). To the authors' knowledge, the prognosis of patients with low‐risk and intermediate‐1–risk MDS by the International Prognostic Scoring System (IPSS) after HMA failure has not been explored comprehensively.
METHODSThe clinical characteristics...
BACKGROUND:The impact of single versus multiple fms‐like tyrosine kinase receptor 3 internal tandem duplication (FLT3‐ITD) mutations on the clinical outcome of patients with acute myelogenous leukemia has not been well studied, and particularly has not been investigated while simultaneously accounting for the quantitative mutation burden.
METHODS:The authors conducted a multivariate analysis of overall...
BACKGROUND:Although most patients with myelodysplastic syndrome (MDS) exhibit bone marrow hypercellularity, a subset of them present with a hypocellular bone marrow. Specific factors associated with poor prognosis have not been investigated in patients with hypocellular MDS.
METHODS:The authors studied a cohort of 253 patients with hypocellular MDS diagnosed at The University of Texas MD Anderson...
BACKGROUND:Standard therapy for older patients with acute myeloid leukemia (AML) has a poor outcome. The authors have designed a combination of clofarabine plus low‐dose cytarabine followed by a prolonged consolidation alternating with decitabine.
METHODS:Sixty patients with a median age of 70 years (range, 60‐81 years) with newly diagnosed AML were included. They received clofarabine 20 mg/m2 intravenously...
BACKGROUND:ARRY‐520 selectively inhibits the mitotic kinesin spindle protein (KSP), which leads to abnormal monopolar spindle formation and apoptosis.
METHODS:A phase 1 trial was conducted to establish the safety and the maximum tolerated dose (MTD) of ARRY‐520 given as a 1‐hour infusion in either a single dose or on a day 1, 3, and 5 divided‐dose schedule per cycle in patients with advanced or refractory...
BACKGROUND:IDH1 and IDH2 gene mutations are novel, recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia (AML).
METHODS:Among 358 patients with AML treated on 4 protocols using high‐dose ara‐C plus idarubicin induction, pretreatment samples were available for 170 (median age 53 years, [range, 17‐73]; 96% ≤65) and were evaluated for IDH1R132, IDH2R172, and IDH2R140...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.